Webinar
on demand
30
Nov
2022
18
00
CET
Tumour sites
Breast cancer drugs and Interstitial Lung Disease (ILD): more news

This session is part of the SPCC Adverse Events Management and Interstitial Lung Disease (ILD) Detection Project. Following the Task Force - held in 2022 - the fourth phase of the project will focus on the results emerged from the discussion on the new strategies to tackle adverse events on Interstitial Lung Disease Cancer.

 

 

Speakers
Discussant
Hope Rugo
Division of Hematology and Oncology at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
Expert
Alfredo Addeo
Oncology Division, University Hospital Geneva, Geneve, Switzerland
Expert
Giampaolo Bianchini
Head Breast Cancer Group, Head clinical translational and immunotherapy research Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy, Milan, Italy
Expert
Veronique Dieras
Senior Medical Oncologist at Centre Eugène-Marquis, Rennes, France
This material is part of Educational Project:
2022 - Adverse Events Management and Interstitial Lung Disease (ILD) Detection Project